LUMO (Lumos Pharma Inc) Earnings per share for the last four quarters

Lumos Pharma Corp (LUMO) - corporate logo

Lumos Pharma, Inc. (LUMO) is implementing AI to personalize therapy for children with growth pathologies. Tracking the annual EPS growth rate over the last 12 months on GURU.Markets, we note that -18.00 captures a new level. The company's potential is based on the creation of oral analogs for injections, although business sustainability depends on the outcomes of LUM-201 tests and the necessity of additional share issuances for R&D.

LUMO lumos-pharma.com Net earnings per share (EPS TTM) (02/11/2024 - 02/20/2024)

LUMO (Lumos Pharma, Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:LUMO (Lumos Pharma Inc)
Core merchandise of Lumos Therapeutics

Investors must find a balance between operational risks and the actual return on capital. For Lumos Pharma, Inc. (LUMO), geopolitical tensions and sanctions complicate international clinical trials, slowing the commercialization of drugs. The current EPS YoY TTM growth rate measures the pace of net income change over a rolling year, reflecting profitability dynamics. This indicator helps identify false breakouts of price ranges. The stability of this metric confirms the business's resilience to external shocks.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months rezolutebio.com (RZLT)|Net earnings per share for the last 12 months lexpharma.com LXRX|Net earnings per share (EPS TTM) MBX (MBX Biosciences)|Altimmune Corp - Earnings per share for the last twelve months|Aardvark Therapeutics Inc. - Net earnings per share (EPS TTM)|SGMT - Net earnings per share (EPS TTM)|BioAge Labs (BIOA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months biomeafusion.com (BMEA)|Earnings per share for the last twelve months Quince Therapeutics, Inc.|Net earnings per share for the last 12 months Fractyl (GUTS)|Net earnings per share for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Net earnings per one share for the last twelve months|Pluri Inc. - Net earnings per share for the last 12 months|Net earnings per share for the trailing year Synlogic Corp|LPCN - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Matinas BioPharma Holdings, Inc. MTNB|SPRB: Net earnings per share (EPS TTM)|Galecto Corp - Earnings per share for the trailing year|CTCX (carmellrx.com) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS